
Epicutaneous immunotherapy (EPIT) shows promise in treating food allergies by leveraging the skin's immunological properties. It minimizes systemic allergen exposure and is suitable for potentially life-threatening food allergies. Various approaches are being explored, including allergen-coated microneedles and occlusive epicutaneous systems. Viaskin, an occlusive patch with native allergen extracts, is a clinically advanced EPIT method. Preclinical studies have shown that Viaskin induces long-lasting T-regulatory cells with broad suppressive effects. Clinical trials in younger patients demonstrate its efficacy and safety, offering a non-invasive therapy without daily activity restrictions. EPIT presents an exciting avenue for improving allergic disorder treatments in the near future.
Like
Save
Share